Wesley Nickens
Family Medicine · Amarillo, TXNPI 1043405913
Payments from drug & device makers
Across 238 payments — averaging $16.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$454
- GSK$393
- Abbott$341
- Johnson & Johnson$338
- Novo Nordisk$301
- Bayer$277
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,018100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 26 | $454 |
| GSK | 33 | $393 |
| Abbott | 18 | $341 |
| Johnson & Johnson | 27 | $338 |
| Novo Nordisk | 8 | $301 |
| Bayer | 11 | $277 |
| Axsome Therapeutics, Inc. | 15 | $224 |
| Otsuka America Pharmaceutical, Inc. | 10 | $200 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $182 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $169 |
| Lilly USA, LLC | 8 | $122 |
| Pfizer | 7 | $121 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $92 |
| Amgen(2 entities) | 7 | $91 |
| Nestle Healthcare Nutrition Inc. | 5 | $81 |
| Biogen | 3 | $66 |
| Antares Pharma, Inc. | 4 | $62 |
| Kyowa Kirin, Inc. | 3 | $55 |
| AstraZeneca | 3 | $53 |
| Novartis | 3 | $48 |
| Arbor Pharmaceuticals, Inc. | 3 | $47 |
| Lundbeck LLC | 2 | $44 |
| Boehringer Ingelheim | 2 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Biohaven Pharmaceuticals, Inc. | 2 | $33 |
| Inspire Medical Systems, Inc. | 1 | $31 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Philips North America LLC | 1 | $14 |
| Optinose US, Inc. | 1 | $13 |
| Merck | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Inogen, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,018 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $33,545 |
| EliquisApixaban | 30 | $26,275 |
| FarxigaDapagliflozin Propanediol | 41 | $25,705 |
| OzempicSemaglutide | 25 | $24,948 |
| MounjaroTirzepatide | 22 | $23,497 |
| VraylarCariprazine Hcl | 14 | $23,304 |
| QuliptaAtogepant | 11 | $11,611 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $11,604 |
| TrintellixVortioxetine Hydrobromide | 14 | $7,161 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 85 | $2,629 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 57 | $2,161 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 11 | $2,086 |
| Gabapentin | 90 | $1,629 |
| Pregabalin | 56 | $1,099 |
| Atorvastatin Calcium | 181 | $1,067 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $53 | $37,30952 claims |
| AbbVieVraylar, Qulipta | $454 | $34,91525 claims |
| GSKTrelegy Ellipta | $393 | $33,54544 claims |
| PfizerEliquis | $121 | $26,27530 claims |
| Novo NordiskOzempic | $301 | $24,94825 claims |
| Lilly USA, LLCMounjaro | $122 | $23,49722 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $182 | $7,16114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Amarillo
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.